Suzette Delaloge

Active 2001–2026

169
Papers
32,898
Citations
88
h-index
159
i10-index

Citations

Citations per year for Suzette Delaloge1926: 1 citations1981: 2 citations1982: 1 citations1993: 3 citations1996: 1 citations1998: 1 citations1999: 2 citations2001: 4 citations2002: 4 citations2003: 6 citations2004: 4 citations2005: 17 citations2006: 17 citations2007: 48 citations2008: 104 citations2009: 99 citations2010: 158 citations2011: 159 citations2012: 191 citations2013: 206 citations2014: 197 citations2015: 257 citations2016: 295 citations2017: 315 citations2018: 391 citations2019: 1,100 citations2020: 1,388 citations2021: 1,462 citations2022: 1,427 citations2023: 1,268 citations2024: 1,839 citations2025: 975 citations2026: 37 citations1927–1980: no citations, so these years are not shown1983–1992: no citations, so these years are not shown1994–1995: no citations, so these years are not shown1997: no citations, so this year is not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,787 citing papers, 21.3% of this breakdownChina: 1,905 citing papers, 10.7% of this breakdownItaly: 1,210 citing papers, 6.8% of this breakdownFrance: 1,181 citing papers, 6.7% of this breakdownUnited Kingdom: 963 citing papers, 5.4% of this breakdownGermany: 847 citing papers, 4.8% of this breakdownSpain: 642 citing papers, 3.6% of this breakdownCanada: 546 citing papers, 3.1% of this breakdownBelgium: 511 citing papers, 2.9% of this breakdownNetherlands: 503 citing papers, 2.8% of this breakdownAustralia: 485 citing papers, 2.7% of this breakdownJapan: 405 citing papers, 2.3% of this breakdown
0%21.3%Other 26.9%

Fields

  • Medicine53.4%
  • Biochemistry, Genetics and Molecular Biology30.6%
  • Immunology and Microbiology9.4%
  • Computer Science2.1%
  • Engineering1.8%
  • Materials Science0.6%
  • Other2.1%

Topics

  • Breast Cancer Treatment Studies6.3%
  • Cancer Immunotherapy and Biomarkers6.1%
  • HER2/EGFR in Cancer Research4.2%
  • Advanced Breast Cancer Therapies4.1%
  • Immunotherapy and Immune Responses4%
  • Cancer Genomics and Diagnostics3%
  • Other72.3%

Coauthors

All papers

Open in search
  1. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 3,214

  2. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2007 cited by 2,969

  3. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 cited by 803

  4. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi - New England Journal of Medicine 2021 cited by 832

  5. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , René Bernards, Konstantinos Tryfonidis, Emiel J. Rutgers, Martine Piccart - New England Journal of Medicine 2016 cited by 2,051

  6. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J Feng, Min Yan, Yan Wang, Qiang Liu, S. Zhang, Michelino De Laurentiis, Armando Santoro, Valentina Guarneri, Marco Colleoni, Clara Natoli, Laura Cortesi, Sabino De Placido, Lorenzo Gianni, Francesco Ferraù, Lorenzo Livi, Alberto Zambelli, Lucia Del Mastro, Giuseppe Tonini, Filippo Montemurro, Giulia Bianchi, R. Pedersini, Salvatore A. Del Prete, Giacomo Allegrini, Giuseppe Naso, Patrizia Vici, D. Loirat, Audrey Mailliez, Franck Priou, Olivier Trédan, F. Dalenc, Christophe Perrin, Joseph Gligorov, Morales-Pancorbo David, Nadine Dohollou, Luís Teixeira, Fabien Brocard, Antoine Arnaud, Suzette Delaloge, Jean‐Philippe Spano, Luigi Mansi, Livia Andrade, Fernanda Damian, José Luiz Pedrini, Sandra M. Aleixo, Roberto Hegg, R. Junior, Mattea Reinisch, Marcus Schmidt, C. Wenzel, E.‐M. Grischke, Andreas Schneeweiß, Marianne Just, Nadia Harbeck, Claudia Schumacher, Ubong Peters, Dorothea Fischer, Helmut Forstbauer, Rüdiger Liersch, Ellen Warner, Nathaniel Bouganim, C. T. Doyle, Julie Price Hiller, Ted Vandenberg, Michel Pavic, Andrew Robinson, Gloria Roldan Urgoiti, Nadia Califaretti, Ahmet Alacacıoğlu, M. Gumus, Bülent Yalçın and 68 more - Annals of Oncology 2021 cited by 729

  7. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke and 509 more - Annals of Oncology 2022 cited by 447

  8. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 291

  9. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Vichnou Poirier-Colame, Suzette Delaloge, Frédérique Penault‐Llorca, Sylvain Ladoire, Laurent Arnould, Joanna Cyrta, Marie-Charlotte Dessoliers, Alexander Eggermont, Marco E. Bianchi, Mikaël J. Pittet, Camilla Engblom, Christina Pfirschke, Xavier Préville, Gilles Uzé, Robert D. Schreiber, Melvyn T. Chow, Mark J. Smyth, Enrico Proietti, Fabrice André, Guido Kroemer, Laurence Zitvogel - Nature Medicine 2014 cited by 1,031

  10. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, François‐Clément Bidard, Barbara Pistilli, Florence Dalenc, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Coraline Dubot, Jean‐Sébastien Frenel, Jean-­Marc Ferrero, Sylvain Ladoire, Jean-Marc FERRERO, Marie‐Ange Mouret‐Reynier, Anne‐Claire Hardy‐Bessard, Alain Lortholary, Anne-Claire HARDY-BESSARD, Camille Chakiba, Laëtitia Stefani, P Soulié, Jean-Philippe Jacquin, Jérôme Edouard Plaza, Florian Clatot, Luís Teixeira, Florian CLATOT, Luis TEIXEIRA, Olfa Derbel, Claire Garnier Tixidre, Catherine Delbaldo, Lionel MOREAU, Caroline Cheneau, Jean-François Paitel, Chantal BERNARD-MARTY, Dominique Spaëth, Dominique Genet, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence Venat‐Bouvet, Valérie Delecroix, Adrien MELIS, Hubert Orfeuvre, Suzanne Nguyen, Éric Legouffe, Alain Zannetti, Romuald Le Scodan, Nadine Dohollou, Philippe DALIVOUST, Olivier Arsène, Nathalie MARQUES, Thierry Petit, Delphine MOLLON, Jérôme Dauba, Nathalie Bonnin, François MORVAN, Miriam Gardner, Adina MARTI, Charles-Briac Levaché, Emma Lachaier, Mihaela ACHILLE, Christophe VALMAR, Ryan Bouaita, Jacques Médioni, Cyril Foa, Chantal BERNARD-MARTY, Francesco Del Piano, Michel GOZY and 19 more - The Lancet Oncology 2022 cited by 317

  11. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2019 cited by 760

  12. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Richard Bryce, Adam Brufsky, for the NALA Investigators - Journal of Clinical Oncology 2020 cited by 609

  13. Personalized early detection and prevention of breast cancer: ENVISION consensus statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Devilee, Suzette Delaloge, Marjanka K. Schmidt, Martin Widschwendter - Nature Reviews Clinical Oncology 2020 cited by 439

  14. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 210

  15. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 103

  16. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giuseppe Curigliano, Jana de Boniface, Suzette Delaloge, A. DeMichele, Carsten Denkert, Gerd Fastner, Florian Fitzal, Prudence A. Francis, H Gamal, Oreste ­Gentilini, Michael Gnant, William J. Gradishar, B. Gulluoglu, Nadia Harbeck, Jörg Heil, Chien Shiun Huang, Jens Huober, Zeping Jiang, Orit Kaidar‐Person, Marleen Kok, Eun‐So Lee, Sherene Loi, S. Loibl, Miguel Martín, Icro Meattini, Monica Morrow, A. H. Partridge, Frédérique Penault‐Llorca, Martine Piccart, Lori J. Pierce, Philip Poortmans, Meredith M. Regan, J. S. Reis-Filho, Isabel T. Rubio, Hope S. Rugo, Emiel J. Rutgers, Cristina Saura, Elżbieta Senkus, Zhi-Ming Shao, Christian F. Singer, Tanja Španič, Beat Thuerlimann, Masakazu Toi, Sara M. Tolaney, Nicholas C. Turner, Andrew Tutt, M.-J. Vrancken Peeters, Toru Watanabe, William P. Weber, Hans Wildiers, B. Xu - Annals of Oncology 2023 cited by 221

  17. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

    Authors: , , , , , , , , , , , - Annals of Oncology 2020 cited by 342

  18. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard and 1 more - The Lancet Oncology 2021 cited by 348

  19. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Death and Differentiation 2021 cited by 166

  20. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fátima Cardoso, Emiel J. Rutgers - The Lancet Oncology 2021 cited by 358

  21. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2019 cited by 257

  22. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 139

  23. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Feng Xu, Alan Auerbach, Marc Buyse, Arlene Chan, Vernon Harvey, Rudolf Tomek, Nicholas J. Robert, Ira Gore, John W. Smith, Norikazu Masuda, S. Di Sean Kendall, William Graydon Harker, Katarína Petráková, Ángel Guerrero‐Zotano, Amparo Ruiz Simón, Zora Neskovic Konstantinovic, Nicholas Iannotti, Pierfrancesco Tassone, Gladys Rodriguez, Noelia Jáñez Martínez, Carmen Crespo Massieu, Snezana Smickoska, Işıl Somali, Uğur Yılmaz, Mirta Garcia Alonso, Adolfo Rosales, Soeren Cold, Ann Knoop, Debra A. Patt, Beth A. Hellerstedt, Serafin Morales Murillo, Ingrid A. Mayer, Julie A. Means‐Powell, Rina Hui, Francis M. Senecal, Richard Hendry De Boer, Zhenzhou Shen, A.A. Luczak, Joanna W.Y. Chui, Janice Tsang, István Láng, Yoshiaki Rai, Yasuo Hozumi, Albert J. ten Tije, Manish Bhandari, Cynthia R. Osborne, Shoichiro Ohtani, Kenji Higaki, Kenichi Watanabe, Kazunori TAGUCHI, Masato Takahashi, Sladjana Filipovic, Vincent Hansen, Vijayarama Phooshkooru Rao, Manish Gupta, Petar Petrov, Bruno Coudert, Željko Vojnović, Zsofia Polya, Toshiko Miyaki, Naohito Yamamoto, Stephen Brincat, Krzysztof Leśniewski-Kmak, Ewa Chmielowska, Ruemu Birhiray, Marc L. Citron, Steven W. Papish, William L. Berry, Sven Tyge Langkjer, José Á. García-Sáenz and 526 more - The Lancet Oncology 2017 cited by 589

  24. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: , , , , , , , , , , , , - European Journal of Cancer 2023 cited by 111